Optimizing Treatment for Patients With Diabetes Mellitus: Glycemic and Nonglycemic Effects

Jay H. Shubrook, Jr. , DO
The Journal of The American Osteopathic Association
Ohio University College of Osteopathic Medicine, Grosvenor Hall, Athens, OH 45701


 Despite an array of medications available in the United States to treat patients with type 2 diabetes mellitus (T2DM), physicians still have not achieved optimal control of this disease. In the present supplement to JAOA—The Journal of the American Osteopathic Association, we look at 3 contributing factors to this phenomenon. Mark D. Baldwin, DO, addresses the topic of cardiovascular risk associated with diabetes mellitus. Steven H. Barag, DO, discusses the advantages of using insulin early in the treatment of patients with T2DM. Finally, Alan J. Garber, MD, PhD, explores incretin-based agents, including their unique nonglycemic benefits.